Pharma Mar S.A. (PHM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharma Mar S.A. (PHM) has a cash flow conversion efficiency ratio of 0.133x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€33.58 Million ≈ $39.26 Million USD) by net assets (€251.83 Million ≈ $294.42 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharma Mar S.A. - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Pharma Mar S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read PHM current and long-term liabilities for a breakdown of total debt and financial obligations.
Pharma Mar S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharma Mar S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
-0.044x |
|
Hankook Tire Worldwide
KO:000240
|
0.016x |
|
CHOROKBAEM COMPANY Co. Ltd
KQ:052300
|
0.032x |
|
Beijing Jingwei Hirain Technologies Co. Ltd. A
SHG:688326
|
-0.001x |
|
Nyfosa AB (publ)
ST:NYF
|
0.012x |
|
BlueNord ASA
OL:BNOR
|
0.553x |
|
DUERR AG UNSP.ADR 1/5
F:DUEB
|
N/A |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
0.023x |
Annual Cash Flow Conversion Efficiency for Pharma Mar S.A. (2002–2025)
The table below shows the annual cash flow conversion efficiency of Pharma Mar S.A. from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see PHM company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €251.83 Million ≈ $294.42 Million |
€53.13 Million ≈ $62.11 Million |
0.211x | +629.35% |
| 2024-12-31 | €208.36 Million ≈ $243.59 Million |
€6.03 Million ≈ $7.05 Million |
0.029x | +141.61% |
| 2023-12-31 | €193.44 Million ≈ $226.15 Million |
€-13.45 Million ≈ $-15.72 Million |
-0.070x | -140.44% |
| 2022-12-31 | €222.96 Million ≈ $260.66 Million |
€38.32 Million ≈ $44.80 Million |
0.172x | +19.09% |
| 2021-12-31 | €177.92 Million ≈ $208.00 Million |
€25.68 Million ≈ $30.02 Million |
0.144x | -94.69% |
| 2020-12-31 | €102.72 Million ≈ $120.09 Million |
€278.94 Million ≈ $326.11 Million |
2.716x | +177.46% |
| 2019-12-31 | €7.46 Million ≈ $8.72 Million |
€-26.14 Million ≈ $-30.56 Million |
-3.505x | -274.86% |
| 2018-12-31 | €17.47 Million ≈ $20.43 Million |
€-16.34 Million ≈ $-19.10 Million |
-0.935x | -1373.18% |
| 2017-12-31 | €22.98 Million ≈ $26.87 Million |
€-1.46 Million ≈ $-1.71 Million |
-0.063x | +63.41% |
| 2016-12-31 | €48.49 Million ≈ $56.70 Million |
€-8.41 Million ≈ $-9.84 Million |
-0.174x | -214.15% |
| 2015-12-31 | €73.04 Million ≈ $85.39 Million |
€11.10 Million ≈ $12.98 Million |
0.152x | -58.70% |
| 2014-12-31 | €60.07 Million ≈ $70.23 Million |
€22.11 Million ≈ $25.85 Million |
0.368x | +11.32% |
| 2013-12-31 | €49.44 Million ≈ $57.79 Million |
€16.34 Million ≈ $19.11 Million |
0.331x | +102.63% |
| 2012-12-31 | €38.73 Million ≈ $45.27 Million |
€6.32 Million ≈ $7.39 Million |
0.163x | +231.48% |
| 2011-12-31 | €34.50 Million ≈ $40.34 Million |
€-4.28 Million ≈ $-5.01 Million |
-0.124x | +80.24% |
| 2010-12-31 | €34.86 Million ≈ $40.76 Million |
€-21.90 Million ≈ $-25.60 Million |
-0.628x | -14.01% |
| 2009-12-31 | €41.14 Million ≈ $48.09 Million |
€-22.67 Million ≈ $-26.50 Million |
-0.551x | +23.75% |
| 2008-12-31 | €49.34 Million ≈ $57.69 Million |
€-35.66 Million ≈ $-41.69 Million |
-0.723x | -45.25% |
| 2007-12-31 | €98.81 Million ≈ $115.52 Million |
€-49.16 Million ≈ $-57.47 Million |
-0.497x | +4.99% |
| 2006-12-31 | €107.17 Million ≈ $125.30 Million |
€-56.11 Million ≈ $-65.60 Million |
-0.524x | -470.66% |
| 2005-12-31 | €360.04 Million ≈ $420.93 Million |
€-33.03 Million ≈ $-38.62 Million |
-0.092x | +80.98% |
| 2003-12-31 | €139.28 Million ≈ $162.83 Million |
€-67.18 Million ≈ $-78.54 Million |
-0.482x | -125.85% |
| 2002-12-31 | €166.90 Million ≈ $195.12 Million |
€-35.64 Million ≈ $-41.67 Million |
-0.214x | -- |
About Pharma Mar S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound deri… Read more